1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Parmax Pharma Ltd.

Parmax Pharma Ltd.

BBSE:PARMAX
136.40
INR
-1.35
(-0.98%)
-3.20EPS
292.18MMarket Cap
Parmax Pharma Ltd.
BSE:PARMAX
(Bombay Stock Exchange)

Recent

price

136.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
- -
- -
- -
- -
- -
31.81
32.11
55.95
70.04
48.78
41.5
29.54
80.81
32.03
49.18
Revenue per Share
- -
-0.09
0.11
0.07
-0.01
-0.02
- -
0.21
1.15
2.02
0.38
-0.28
-15.37
-6
-11
-3.2
Basic EPS, GAAP
- -
-0.09
-0.04
-0.17
-0.01
-1.86
-0.94
-6.65
1.14
1.01
-2.09
-1.62
-4.77
-3.89
-8.61
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.66
10.58
10.68
11.08
12.2
12.18
12.18
12.39
13.54
15.55
15.93
15.65
0.28
-5.32
-16.43
- -
Book Value per Share
10.66
10.58
10.68
11.08
12.2
12.18
12.18
12.39
13.54
15.55
15.93
15.65
0.28
-5.32
-16.43
- -
Tangible Book Value per Share
3
3
3
3
4
4
4
4
4
4
4
4
4
3
4
4
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
119
120
209
262
183
154
111
282
121
184
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-0.07
0.69
5.89
7.55
5.67
5.21
-42.07
-2.75
-38.37
-20.45
Operating Margin (%)
- -
- -
- -
- -
- -
- -
11
10
10
19
19
19
17
10
10
13
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
4
8
1
-1
-58
-21
-42
-12
Net Income, GAAP
- -
- -
9.25
37.53
133.13
253.84
67.2
19.8
41.33
37.57
53.34
325.63
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
0.66
2.05
2.88
0.78
-0.67
-52.03
-7.42
-34.34
-6.5
Profit Margin (%)
14
14
15
15
16
16
-10
-8
-14
-9
-8
4
-34
-41
-60
- -
Working Capital
9
9
9
8
5
10
20
53
50
54
45
45
59
77
115
- -
LT Debt
40
40
40
41
46
46
46
46
51
58
60
59
1
-20
-61
- -
Total Equity
- -
- -
-0.36
-0.3
0.32
-0.22
-0.05
0.79
4.29
8.36
2.5
-7.89
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
0.74
0.46
-0.08
-0.22
0.19
1.09
4.86
8.9
2.69
-8.63
- -
- -
- -
- -
Return on Capital (%)
- -
-0.75
0.91
0.55
-0.09
-0.17
0.01
1.71
8.84
13.86
2.4
-1.76
-192.93
- -
- -
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
5
- -
LT Borrowings
- -
115
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
126
106
292

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
167
- -
Cash, Cash Equivalents & STI
- -
6
- -
Accounts Receivable, Net
- -
32
- -
Inventories
- -
78
- -
Total Current Liabilities
- -
227
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
5
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-185.05%
-375.25%
209.14%
Free Cash Flow
1,449.87%
-3.53%
139.75%
Net Income, GAAP
2,013.2%
1,041.19%
98.62%
Sales/Revenue/Turnover
- -
4.79%
-57.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
78
21
63
48
282
2026
19
25
43
33
121
2027
82
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
-1.88
-1.05
-4
-6
2026
-2.04
-5.56
-1.96
-1.56
-11
2027
5.88
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Parmax Pharma Limited Parmax Pharma Limited (PARMAX.BO) manufactures and sells bulk drugs, drug intermediates, and specialty chemicals in India. The company produces active pharmaceutical ingredients including historical products such as Ampicillin, Amoxycillin, Cephalexin, and Nalidixic Acid; it also engages in contract manufacturing operations using Quality by Design techniques, current Good Manufacturing Practices, and flow chemistry for hazardous and cryogenic reactions. Operations leverage in-house production capabilities and strategic sourcing partnerships to serve pharmaceutical customers primarily in the Indian market. Incorporated in 1994 and headquartered in Rajkot, Gujarat, at Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, the company went public via IPO in 1996 before a temporary discontinuation of activities. Parmax Pharma Limited plans to expand into formulations of tablets, capsules, ointments, and injectables; it advances sustainable manufacturing through a modular plant commissioning for intermediate-to-API processes and maintains leadership via new product offerings and cost efficiencies.